Variable | All patients | Low ApoA1 group (n = 125) | High ApoA1 group (n = 103) | statistics | P value |
---|---|---|---|---|---|
Gender(n) | 228 | χ2 = 10.638 | 0.001 | ||
Male/Female, n | 133/95 | 85/40 | 48/55 | ||
Age [years, median (quartile)] | 62(51,73) | 63(28 ~ 86) | 61(16 ~ 90) | Z = -1.881 | 0.06 |
BM Blast[%, median (quartile)] | 4(1,9) | 6(0 ~ 19.5) | 3(0 ~ 19) | Z = -2.718 | 0.007 |
Peripheral Blood | |||||
NE [× 109/L, median (quartile)] | 1.2(0.7,2.1) | 1.1(0 ~ 7.4) | 1.3(1.1 ~ 6.9) | Z = -1.111 | 0.266 |
HB [g/L, median (quartile)] | 7.5(6.2,9.9) | 67(22 ~ 142) | 88(50 ~ 142) | Z = -5.315 | <0.0001 |
PLT [×109/L, median (quartile)] | 52(28,94) | 46(4 ~ 332) | 60(2 ~ 434) | Z = -2.809 | 0.005 |
ALB [g/L, median (quartile)] | 39.4(35.4,43.0) | 37.1(23.3 ~ 48.9) | 42.0(18.3 ~ 60.2) | Z = -6.275 | <0.0001 |
CHO [mmol/L, median (quartile) | 3.56(2.78,4.26) | 3.13(1.28 ~ 7.62) | 4.07(2.01 ~ 8.92) | Z = -6.564 | <0.0001 |
LDH [U/L, median (quartile) | 205.5(167.0,269.8) | 206(100 ~ 930) | 203(94 ~ 618) | Z = -0.337 | 0.736 |
CRP [mg/L, median (quartile) | 2.24(0.83,6.13) | 2.7(0.33 ~ 33.69) | 1.53(0.15 ~ 19.21) | Z = -2.477 | 0.013 |
HDL [mmol/L, median (quartile) | 0.91(0.68,1.15) | 0.73(0.09 ~ 1.48) | 1.15(0.63 ~ 2.27) | Z = -10.316 | <0.0001 |
LDL [mmol/L, median (quartile) | 2.08(1.60,2.59) | 1.84(0.32 ~ 5.07) | 2.33(0.8 ~ 5.75) | Z = -5.151 | <0.0001 |
ApoB [g/L, median (quartile)] | 0.69(0.55,0.87) | 0.63(0.23 ~ 1.29) | 0.76(0.26 ~ 1.97) | Z = -4.670 | <0.0001 |
ApoA1[g/L, median (quartile)] | 1.00(0.82,1.18) | 0.84(0.34 ~ 1.02) | 1.19(1.03 ~ 2.36) | Z = -12.989 | <0.0001 |
2016 WHO classification | χ2 = 14.801 | 0.039 | |||
MDS-SLD, % (n/n) | 10.1% (23/228) | 6.4% (8/125) | 14.6% (15/103) | ||
MDS-MLD, % (n/n) | 27.6% (63/228) | 25.6% (32/125) | 3.0% (31/103) | ||
MDS-RS-SLD, % (n/n) | 2.2% (5/228) | 1.6% (2/125) | 2.9% (3/103) | ||
MDS-RS-MLD, % (n/n) | 4.4% (10/228) | 3.2% (4/125) | 5.8% (6/103) | ||
MDS-5q-, % (n/n) | 2.6% (6/228) | 1.6% (2/125) | 3.9% (4/103) | ||
MDS-EB1, % (n/n) | 25.9% (59/228) | 27.2% (34/125) | 24.3% (25/103) | ||
MDS-EB2, % (n/n) | 21.1% (48/228) | 28.8% (36/125) | 11.7% (12/103) | ||
MDS-U, % (n/n) | 6.1% (14/228) | 5.6% (7/125) | 6.8% (7/103) | ||
IPSS-R cytogenetic risk group | χ2 = 2.738 | 0.603 | |||
Very good, % (n/n) | 1.0% (2/194) | 1.0% (1/97) | 1.0% (1/97) | ||
Good, % (n/n) | 63.9% (124/194) | 59.8% (58/97) | 68.0% (66/97) | ||
Intermediate, % (n/n) | 20.6% (40/194) | 24.7% (24/97) | 16.5% (16/97) | ||
Poor, % (n/n) | 5.2% (10/194) | 4.1% (4/97) | 6.2% (6/97) | ||
Very poor, % (n/n) | 9.3% (18/194) | 10.3% (10/97) | 8.2% (8/97) | ||
IPSS-R risk category | χ2 = 10.349 | 0.035 | |||
Very low, % (n/n) | 6.7% (13/194) | 3.1% (3/97) | 10.3% (10/97) | ||
Low, % (n/n) | 18.6% (36/194) | 14.4% (14/97) | 22.7% (22/97) | ||
Intermediate, % (n/n) | 34.5% (67/194) | 34.0% (33/97) | 35.1% (34/97) | ||
High, % (n/n) | 21.1% (41/194) | 22.7% (22/97) | 19.6% (19/97) | ||
Very high, % (n/n) | 19.1% (37/194) | 25.8% (25/97) | 12.4% (12/97) | ||
IPSS-R score [median (quartile)] | 4.5(3.0,6.0) | 4.5(2.0 ~ 10.0) | 4.0(1.0 ~ 9.0) | Z = -3.188 | 0.001 |
Gene mutation, % (n/n) | 64.1% (41/64) | 71.4% (20/28) | 58.3% (21/36) | χ2 = 1.173 | 0.279 |
Leukemia transformation, % (n/n) | 11.4% (26/228) | 12.8% (16/125) | 9.7% (10/103) | χ2 = 0.534 | 0.465 |
Complex karyotype, % (n/n) | 18.0% (35/194) | 21.6% (21/97) | 14.4% (14/97) | χ2 = 1.708 | 0.191 |
With cardiovascular comorbidity, % (n/n) | 21.9% (50/228) | 21.6% (27/125) | 22.3% (23/103) | χ2 = 0.018 | 0.895 |